Lantus Cost in North Dakota 2026: Prices, Medicaid, and Your Cheapest Options

What Does Lantus Actually Cost in North Dakota Right Now?

The sticker price on Lantus is steep, but the real out-of-pocket number most North Dakotans pay is far lower. Sanofi's manufacturer wholesale acquisition cost sits near $340 per month for a standard 10 mL vial. At North Dakota retail pharmacies in 2026, cash-pay patients who use a pharmacy discount card typically pay roughly $35 per month for the same vial.

That gap between $340 and $35 exists because discount aggregators negotiate lower rates with pharmacy benefit managers and pass the savings directly to the consumer. GoodRx, RxSaver, and NeedyMeds all list North Dakota prices in this range. The Centers for Medicare and Medicaid Services insulin cost-sharing cap of $35 per month for Medicare Part D beneficiaries applies nationally, including North Dakota enrollees, under the Inflation Reduction Act provisions that took effect in 2023. [1]

Insulin pricing in the United States has been studied extensively. A 2019 analysis in JAMA Internal Medicine documented that list prices for basal insulins, including glargine, increased more than 1,100% between 1996 and 2019, a pattern that drove federal legislative action. [2] The practical consequence for North Dakotans: always check a discount card before paying a pharmacy's posted shelf price, because the two numbers can differ by hundreds of dollars per month.

For context on glargine's clinical standing, the ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 showed that insulin glargine in people with dysglycemia neither increased nor decreased rates of cardiovascular events compared with standard care over a median follow-up of 6.2 years, establishing its long-term safety profile. [3] That data underpins confidence in long-term prescribing, which makes cost sustainability a genuine clinical concern for prescribers.

Sanofi's own FDA-approved prescribing information confirms the standard adult starting dose of 0.2 units per kilogram or 10 units once daily, titrated to a fasting glucose target. [4] At typical doses, most adults use one vial per month, keeping the cost calculation straightforward.

Does North Dakota Medicaid Cover Lantus?

North Dakota Medicaid does not cover Lantus as of 2026. This is a formulary decision, not a statutory prohibition. The ND Medicaid preferred drug list favors biosimilar and alternative basal insulins over branded glargine. [5]

Patients enrolled in ND Medicaid who require basal insulin coverage should ask their provider to prescribe a covered alternative. Basaglar (insulin glargine-yfgn), a biosimilar to Lantus, is often on state Medicaid preferred drug lists at lower cost. Toujeo (insulin glargine U-300) and Tresiba (insulin degludec) are separate agents with distinct formulary standings. If a prescriber determines that Lantus is medically necessary, a prior authorization request is the standard pathway. The American Diabetes Association's 2024 Standards of Care state that "insulin access and affordability remain significant barriers to optimal diabetes management." [6]

Children and adults with type 1 diabetes who rely on Medicaid face particular challenges when a preferred basal insulin causes hypoglycemia or erratic absorption. In those cases, documenting clinical failure of the preferred agent strengthens a prior authorization. The FDA's guidance on interchangeable biological products is relevant here because substitution policies vary by state. [7]

For Medicaid recipients who cannot get coverage approved, the 503A compounded glargine pathway described in the next section may represent the most accessible zero-cost option, provided they meet the clinical criteria for compounded prescribing.

Is Compounded Insulin Glargine Legal in North Dakota?

Compounded insulin glargine is legal in North Dakota when prepared by a licensed 503A compounding pharmacy and prescribed by a licensed practitioner for an individual patient. This is a specific legal framework, not a gray area. [8]

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. Under 503A, a pharmacy may compound a drug product that is not commercially available or that meets a specific patient need documented by a licensed practitioner. Insulin glargine is commercially available, so the compounding rationale typically rests on cost access or a documented clinical need for a customized formulation or concentration. Prescribers must evaluate each patient individually. [9]

The FDA has noted that compounded drugs are not FDA-approved and have not undergone the same review for safety, efficacy, and quality as their branded counterparts. [10] This does not mean they are unsafe; it means quality depends on the compounding pharmacy's USP 797 compliance. North Dakota patients who obtain compounded glargine should confirm their pharmacy holds state licensure and follows USP Chapter 797 sterile compounding standards. [11]

Through telehealth platforms operating in North Dakota, compounded insulin glargine programs can effectively cost patients $0 per month when the compound is provided as part of a subscription care model. This is the single lowest-cost option available in the state for patients who qualify.

A practical prescribing decision framework for North Dakota clinicians: first check whether the patient has Medicare Part D (cap applies at $35), then check commercial insurance formulary, then check ND Medicaid preferred drug list and consider prior authorization or a covered biosimilar, then evaluate Sanofi's Insulins Valyou program for uninsured patients, and lastly consider a licensed 503A compound if cost remains prohibitive and clinical criteria are met.

How Sanofi Savings Programs Work in North Dakota

Sanofi operates two programs that directly reduce Lantus costs for North Dakota patients.

The Insulins Valyou Savings Program caps out-of-pocket cost at $99 per month for uninsured or underinsured patients. Eligible patients must be U.S. residents, not enrolled in any federal insurance program (including Medicare or Medicaid), and obtain their insulin from a participating retail pharmacy. Enrollment is completed online or by phone with no income threshold. [12]

The Sanofi Patient Assistance Program (PAP) provides Lantus at no cost to patients below 400% of the federal poverty level who lack insurance coverage for insulin. The application requires proof of income and a prescriber signature. Processing typically takes 2 to 4 weeks. Patients experiencing an access emergency may receive a bridge supply while the application is reviewed. [12]

Neither program applies to patients with Medicaid or Medicare, which is why the compounded glargine pathway or a biosimilar prescription may be more practical for that population. A 2023 Health Affairs analysis found that manufacturer patient assistance programs reach fewer than 30% of eligible low-income patients, largely due to enrollment friction. [13] North Dakota patients should be aware that eligibility confirmation can be completed in a single phone call; the barrier is awareness, not complexity.

Lantus and Commercial Insurance in North Dakota

Commercial insurance coverage for Lantus in North Dakota varies substantially by plan. Most Blue Cross Blue Shield of North Dakota plans, Medica, and Sanford Health Plan formularies tier Lantus as a Tier 3 or Tier 4 drug, meaning higher copays than for Tier 1 generics. Copays at Tier 3 typically run $60 to $90 per 30-day supply, though exact amounts depend on plan year and deductible status. [14]

Patients who have met their deductible and have a Tier 3 benefit will pay that copay. Patients in a high-deductible plan who have not met their deductible will pay closer to the pharmacy's discounted rate, which is often lower than the insurance copay until the deductible is satisfied. In that specific scenario, using a GoodRx coupon instead of insurance may produce a lower bill. This is legal; patients may choose not to run a claim through insurance for a specific fill.

The Affordable Care Act requires non-grandfathered plans to cover preventive services without cost-sharing, but insulin is not classified as a preventive service under current USPSTF recommendations. [15] Coverage therefore depends entirely on formulary placement. Patients appealing a Tier 4 placement can submit documentation from their prescriber that Lantus is medically necessary relative to covered alternatives.

A 2021 study in Diabetes Care (N=3,779) found that one in four insulin-dependent adults reported rationing insulin due to cost, with rates highest among uninsured and Medicaid-enrolled individuals. [16] That figure underscores why understanding every available cost pathway matters clinically, not just administratively.

Getting Lantus via Telehealth in North Dakota

Telehealth prescribing of Lantus is permitted in North Dakota. A licensed prescriber holding an active North Dakota DEA registration (where applicable) and a state license may prescribe insulin glargine after a synchronous audio-video evaluation or, in some circumstances, an asynchronous assessment that meets state telehealth standards. [17]

North Dakota follows the Interstate Medical Licensure Compact, which allows providers licensed in other IMLC member states to obtain expedited licensure in North Dakota. [18] This means a board-certified endocrinologist or internist practicing remotely through a telehealth platform can legally prescribe Lantus or compounded glargine to a North Dakota patient without a prior in-person visit.

For patients in rural North Dakota, where the nearest endocrinology practice may be more than 100 miles away, telehealth prescribing closes a substantial geographic access gap. The Centers for Disease Control and Prevention reports that 10.5% of North Dakota adults have diagnosed diabetes, slightly above the national average of 10.2%. [19] Given that proportion, and the state's low population density, telehealth insulin management is not a convenience feature but a structural necessity.

Patients should verify that any telehealth platform they use has a prescriber licensed in North Dakota and that the platform's pharmacy fulfillment partner is a licensed North Dakota or NABP-accredited out-of-state pharmacy.

Comparing Basal Insulin Options by Cost in North Dakota

Lantus is one of several basal insulin options. Cost comparison is clinically relevant because biosimilars and follow-on products can achieve similar glycemic control at lower price points for many patients.

Basaglar (insulin glargine-yfgn, Eli Lilly) is an FDA-approved follow-on biological product to Lantus and shares the same amino acid sequence. The FDA designates it as a biosimilar, not an interchangeable product with Lantus. [20] Its retail price in North Dakota with discount cards runs roughly $25 to $40 per month, similar to branded Lantus cash pricing. However, Basaglar appears on some North Dakota commercial formularies at a lower tier than Lantus, which can translate to meaningfully lower copays.

Semglee (insulin glargine-yfgn, Viatris/Biocon) holds the FDA's first interchangeable biosimilar designation for a basal insulin analog. [21] Interchangeability means a pharmacist may substitute Semglee for Lantus without a new prescription, subject to state law. North Dakota pharmacy law permits this substitution when the prescriber has not marked "dispense as written." Semglee's cash price is often below $30 per month in North Dakota. For patients on ND Medicaid, Semglee's formulary status may differ from Lantus.

Rezvoglar (insulin glargine-aglr, Eli Lilly) launched in 2023 at a list price of $92.00 per vial, roughly 78% below Lantus list price, though this is still the wholesale acquisition cost, not the retail cash price. [22]

The ADA's 2024 Standards of Care note that "when initiating basal insulin, the lowest-cost option that meets the patient's clinical needs should be considered." [6] For most North Dakota patients without strong clinical reasons to prefer one glargine product over another, the cheapest covered option on their formulary or through a discount program is the appropriate starting point.

What to Tell Your Prescriber Before Your Next Fill

Before your next Lantus fill in North Dakota, three specific actions may reduce your cost immediately.

Ask your prescriber to check whether your insurance formulary covers Basaglar or Semglee at a lower tier. If clinical equivalence is acceptable for your situation, a simple prescription change takes effect at the next fill. No dose change is required when switching between insulin glargine reference products and biosimilars at the same unit concentration (U-100); however, Toujeo is U-300 and requires dose recalculation. [4]

Ask whether you qualify for Sanofi's Insulins Valyou Savings Program. If you are uninsured and above the Medicaid income threshold, this program provides a direct cost ceiling of $99 per month without requiring income verification. [12]

Ask whether a licensed 503A telehealth platform operating in North Dakota can manage your insulin glargine prescribing. Platforms that include compounded glargine in their care model may provide the medication at $0 per month as part of a monthly membership fee. Confirm that the compound is prepared under USP 797 standards and that the prescribing clinician holds a North Dakota license. [8]

The CDC estimates that total medical costs attributable to diabetes in the United States exceed $327 billion annually, with direct medical costs representing $237 billion of that figure. [23] At the individual patient level in North Dakota, choosing the right access pathway for basal insulin can mean the difference between $0 and $340 per month for the same therapeutic effect.

For Medicare Part D enrollees in North Dakota: as of January 1, 2023, your cost-sharing for all covered insulins is capped at $35 per 30-day supply under the Inflation Reduction Act, regardless of your plan's deductible. Confirm with your Part D plan that Lantus or your prescribed basal insulin is on the formulary, because the cap applies to covered insulins only. [1]